Related Experiment Video

Updated: Dec 5, 2025

Monitoring Changes in Human Umbilical Vein Endothelial Cells upon Viral Infection Using Impedance-Based Real-Time Cell Analysis
07:56

Monitoring Changes in Human Umbilical Vein Endothelial Cells upon Viral Infection Using Impedance-Based Real-Time Cell Analysis

Published on: May 5, 2023

641

Targeting the Vascular Endothelium in the Treatment of COVID-19

Tatsiana Suvorava1, Wayne Kaesemeyer2

  • 1Institute of Pharmacology and Clinical Pharmacology, University Hospital, Duesseldorf, Germany; and.

Journal of Cardiovascular Pharmacology
|October 20, 2020
PubMed

Insights

Targeting the vascular endothelium offers new therapeutic strategies for coronavirus disease 2019 (COVID-19) complications. This approach aims to mitigate risks like pulmonary endotheliitis and cardiovascular collapse in COVID-19 patients.

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases
  • Endothelial Biology

Background:

  • The vascular endothelium plays a critical role in the pathophysiology of severe coronavirus disease 2019 (COVID-19).
  • Recognized COVID-19 complications include pulmonary endotheliitis, cytokine storm, endotoxic shock, and cardiovascular collapse, all linked to endothelial dysfunction.
  • Endothelial cells are increasingly understood as key players in COVID-19's severe manifestations.

Purpose of the Study:

  • To explore therapeutic strategies targeting the vascular endothelium in COVID-19 management.
  • To highlight the importance of the endothelium in preventing severe COVID-19 outcomes.
  • To provide a perspective on endothelial-focused treatments for COVID-19 complications.

Main Methods:

  • Review of current literature on COVID-19 pathophysiology and endothelial function.
  • Analysis of potential therapeutic targets within the vascular endothelium.
  • Synthesis of existing and novel treatment strategies for endothelial protection.

Main Results:

  • Endothelial dysfunction is a central mechanism in major COVID-19 complications.
  • Targeting the endothelium presents a promising avenue for novel therapeutic interventions.
  • Strategies may include anti-inflammatory, anti-thrombotic, and barrier-protective approaches.

Conclusions:

  • Therapeutic strategies focused on the vascular endothelium are crucial for managing COVID-19 complications.
  • Protecting endothelial integrity can reduce the severity of pulmonary and cardiovascular issues in COVID-19.
  • An endothelium-centric approach should be integrated into the comprehensive treatment of COVID-19.

More Related Videos

In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium10:18

In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium

Published on: May 6, 2018

9.6K
Assessment of Vascular Regeneration in the CNS Using the Mouse Retina07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

14.7K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
309
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
338
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
345